• 1
    Revicki DA, Murray M. Assessing health-related quality of life outcomes of drug treatments for psychiatric disorders. CNS Drugs 1994; 1: 465476.
  • 2
    Dobre D, Van Jaarsveld CH, DeJongste MJ, Haaijer Ruskamp FM, Ranchor AV. The effect of beta-blocker therapy on quality of life in heart failure patients: A systematic review and meta-analysis. Pharmacoepidemiol. Drug Saf. 2007; 16: 152159.
  • 3
    Browne S, Roe M, Lane A et al. Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr. Scand. 1996; 94: 118124.
  • 4
    Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984; 10: 388398.
  • 5
    Skantze K, Malm U, Dencker SJ, May PR, Corrigan P. Comparison of quality of life with standard of living in schizophrenic out-patients. Br. J. Psychiatry 1992; 161: 797801.
  • 6
    Lehman AF. The effects of psychiatric symptoms on quality of life assessments among the chronic mentally ill. Eval. Program Plann. 1983; 6: 143151.
  • 7
    Lehman AF. The well-being of chronic mental patients. Arch. Gen. Psychiatry 1983; 40: 369373.
  • 8
    Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation. Qual. Life Res. 1997; 6: 2126.
  • 9
    Wilkinson G, Hesdon B, Wild D et al. Self-report quality of life measure for people with schizophrenia: The SQLS. Br. J. Psychiatry 2000; 177: 4246.
  • 10
    Kaneda Y, Imakura A, Fujii A, Ohmori T. Schizophrenia Quality of Life Scale: Validation of the Japanese version. Psychiatry Res. 2002; 113: 107113.
  • 11
    Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: The impact of psychopathology, attitude toward medication, and side effects. J. Clin. Psychiatry 2004; 65: 932939.
  • 12
    Karow A, Moritz S, Lambert M, Schoder S, Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005; 38: 320326.
  • 13
    Kugo A, Terada S, Ishizu H et al. Quality of life for patients with schizophrenia in a Japanese psychiatric hospital. Psychiatry. Res. 2006; 144: 4956.
  • 14
    Norman RM, Malla AK, McLean T et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr. Scand. 2000; 102: 303309.
  • 15
    Gaite L, Vazquez-Barquero JL, Borra C et al. Quality of life in patients with schizophrenia in five European countries: The EPSILON study. Acta Psychiatr. Scand. 2002; 105: 283292.
  • 16
    Ho BC, Nopoulos P, Flaum M, Arndt S, Andreasen NC. Two-year outcome in first-episode schizophrenia: Predictive value of symptoms for quality of life. Am. J. Psychiatry 1998; 155: 11961201.
  • 17
    Packer S, Husted J, Cohen S, Tomlinson G. Psychopathology and quality of life in schizophrenia. J. Psychiatry Neurosci. 1997; 22: 231234.
  • 18
    Lewis R. Should cognitive deficit be a diagnostic criterion for schizophrenia? J. Psychiatry Neurosci. 2004; 29: 102113.
  • 19
    Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 1996; 153: 321330.
  • 20
    Heinrichs RW. Meta-analysis and the science of schizophrenia: Variant evidence or evidence of variants? Neurosci. Biobehav. Rev. 2004; 28: 379394.
  • 21
    Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry 1994; 36: 717725.
  • 22
    Matsui M, Sumiyoshi T, Arai H, Higuchi Y, Kurachi M. Cognitive functioning related to quality of life in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008; 32: 280287.
  • 23
    Meltzer HY, Thompson PA, Lee MA, Ranjan R. Neuropsychologic deficits in schizophrenia: Relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 1996; 14: 27S33S.
  • 24
    Wegener S, Redoblado-Hodge MA, Lucas S, Fitzgerald D, Harris A, Brennan J. Relative contributions of psychiatric symptoms and neuropsychological functioning to quality of life in first-episode psychosis. Aust. N. Z. J. Psychiatry 2005; 39: 487492.
  • 25
    Addington J, Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr. Bull. 1999; 25: 173182.
  • 26
    Aksaray G, Oflu S, Kaptanoglu C, Bal C. Neurocognitive deficits and quality of life in outpatients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002; 26: 12171219.
  • 27
    Heslegrave RJ, Awad AG, Voruganti LN. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J. Psychiatry Neurosci. 1997; 22: 235243.
  • 28
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC, 1994.
  • 29
    Inagaki A, Inada T, Fujii A et al. Equivalent Doses of Psychotropic Drugs. Seiwa shoten, Tokyo, 1999.
  • 30
    Hofer A, Baumgartner S, Bodner T et al. Patient outcomes in schizophrenia II: The impact of cognition. Eur. Psychiatry 2005; 20: 395402.
  • 31
    Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261276.
  • 32
    Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five-factor model of schizophrenia. Initial validation. J. Nerv. Ment. Dis. 1994; 182: 631638.
  • 33
    Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: Replication across samples. Schizophr. Res. 1995; 14: 229234.
  • 34
    Kashima H, Kato M. Tests for frontal function-pattern of frontal dysfunction and its assessment. Shinkei Kenkyu No Shimpo 1993; 37: 93110 (in Japanese).
  • 35
    Kobayashi S. Wisconsin Card Sorting Test (WCST). Nippon Rinsho 2003; 61 (Suppl. 9): 344349 (in Japanese).
  • 36
    Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res. 1988; 26: 223238.
  • 37
    Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp. Community Psychiatry 1990; 41: 892897.
  • 38
    Ginsberg DL, Schooler NR, Buckley PF, Harvey PD, Weiden PJ. Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning. CNS Spectr. 2005; 10: 115.
  • 39
    Taniguchi T, Sumitani S, Aono M et al. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms. Hum. Psychopharmacol. 2006; 21: 439445.
  • 40
    Yamauchi K, Aki H, Tomotake M et al. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Psychiatry Clin. Neurosci. 2008; 62: 404411.
  • 41
    The WHOQoL Group. Development of the World Health Organization WHOQoL-BREF quality of life assessment. Psychol. Med. 1998; 28: 551558.
  • 42
    Cornblatt BA, Winters L, Erlenmeyer-Kimling L. Attentional markers of schizophrenia: Evidence from the New York High Risk Study. In : SchulzSC, TammingaCA (eds). Schizophrenia: Scientific Progress. Oxford University Press, New York, 1989; 8392.
  • 43
    Prouteau A, Verdoux H, Briand C et al. Cognitive predictors of psychosocial functioning outcome in schizophrenia: A follow-up study of subjects participating in a rehabilitation program. Schizophr. Res. 2005; 77: 343353.